GLP-1 Drug Use for Weight Loss and Diabetes Varies Widely Across States
State-level variation in the use of glucagon-like peptide-1 receptor agonists for weight loss and diabetes: a real-world analysis.
Background
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of medications increasingly prescribed for the management of type 2 diabetes and obesity. These powerful drugs, including semaglutide and tirzepatide, have demonstrated significant efficacy in improving glycemic control and promoting substantial weight loss. Despite their proven benefits, the extent to which their utilization varies geographically across different U.S. states for these critical health conditions remains largely unexplored.
Study Design
Population
The study examined the utilization of GLP-1 RAs among patients with type 2 diabetes and obesity across different U.S. states.
Intervention
The intervention studied was the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, for type 2 diabetes and obesity.
Outcome
The primary outcome measured was the geographical variation in the utilization of GLP-1 RAs across different U.S. states for type 2 diabetes and obesity.